

CITATION REPORT

List of articles citing

Taxol: a novel investigational antimicrotubule agent

DOI: 10.1093/jnci/82.15.1247

Journal of the National Cancer Institute, 1990, 82, 1247-59.

Source: <https://exaly.com/paper-pdf/21886136/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
921	The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. 1991 , 52, 35-84		252
920	THE IMPACT OF NATIONAL CANCER ACT. <i>Journal of the National Cancer Institute</i> , 1991 , 83, 1797-1797	9.7	11
919	TAXANE DITERPENE SYNTHESIS STRATEGIES. A REVIEW. 1991 , 23, 465-543		105
918	HPLC Separation of Taxol and Cephalomannine. 1991 , 14, 659-665		64
917	Sequences of taxol and cisplatin: a phase I and pharmacologic study. 1991 , 9, 1692-703		340
916	Neurologic Complications of Chemotherapy. 1991 , 9, 955-967		93
915	Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. 1991 , 88, 547-51		122
914	Separation of taxol from related taxanes in <i>Taxus brevifolia</i> extracts by isocratic elution reversed-phase microcolumn high-performance liquid chromatography. 1991 , 587, 300-305		25
913	Progress and challenges in the global effort against cancer. 1991 , 117, 290-4		
912	Asymmetric synthesis of β -lactams and n-benzoyl-3-phenylisoserines via the Staudinger reaction. 1991 , 32, 3151-3154		39
911	Multidrug resistant transgenic mice as a novel pharmacologic tool. 1991 , 13, 381-7		27
910	Enzymatic regulation of estradiol-17 beta concentrations in human breast cancer cells. 1992 , 20, 145-54		20
909	Oncology. 1991 , 265, 3141		3
908	THE MEDICAL STUDENT SECTION OF JAMA. 1991 , 266, 1277		
907	Die multidrug resistente transgene Maus: In-vivo-Charakterisierung des menschlichen MDR-1 Genes. 1991 , 22, 85-91		
906	Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. 1992 , 257, 99-103		446
905	New therapies for ovarian cancer. 1992 , 10, 307-15		12

904	Abstracts. 1992 , 10, 1-41	30
903	2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. 1992 , 89, 2272-6	62
902	Ovarian cancer--unrealistic expectations. 1992 , 327, 197-200	16
901	Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. 1992 , 10, 1748-53	231
900	Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity. 1992 , 256, 1172-8	264
899	Taxol. 1992 , 339, 1447-1448	5
898	The next generation: new chemotherapy agents for the 1990s. 1992 , 8, 83-94	2
897	Mechanism of action of taxol. 1992 , 13, 134-6	469
896	Factors influencing the in vitro production of radiolabeled taxol by Pacific yew, <i>Taxus brevifolia</i> . 1992 , 84, 65-74	43
895	Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). 1992 , 17, 221-37	1141
894	Low resolution structure of microtubules in solution. Synchrotron X-ray scattering and electron microscopy of taxol-induced microtubules assembled from purified tubulin in comparison with glycerol and MAP-induced microtubules. 1992 , 226, 169-84	129
893	The Current Role of Radiotherapy in the Management of Ovarian Cancer. 1992 , 6, 895-913	4
892	Experimental Chemotherapy. 1992 , 6, 927-940	4
891	The chemistry of C-aromatic taxane derivatives atropisomer control of reaction stereochemistry. 1992 , 48, 7013-7032	23
890	Taxol Photoaffinity Label: 7-(p-Azidobenzoyl)taxol Synthesis and Biological Evaluation. 1992 , 2, 735-738	24
889	Semisynthesis and biological activity of taxol analogues: baccatin III 13-(N-benzoyl-(2?R,3?S)-3?-(p-tolyl)isoserinate), baccatin III 13-(N-(p-toluoyl)-2?R,3?S)-3?-phenylisoserinate), baccatin III 13-(N-benzoyl-(2?R,3?S)-3?-(p-trifluoromethylphenyl)isoserinate), and baccatin III 13-(N-(p-trifluoromethylbenzoyl)-2?R,3?S)-3?-phenylisoserinate). 1992 , 2, 1751-1754	10
888	Synthesis of a photoreactive taxol side chain. 1992 , 2, 91-94	8
887	Novel Biologically Active Taxol Analogues: Baccatin III 13-(N-(p-chlorobenzoyl)-(2?R,3?S)-3?-phenylisoserinate) and Baccatin III 13-(N-benzoyl-(2?R,3?S)-3?-(p-chlorophenyl)isoserinate). 1992 , 2, 295-298	34

886	Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo. 1992 , 31, 255-7	15
885	Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. 1992 , 30, 444-50	118
884	Taxol administered as a 120 hour infusion. 1992 , 10, 275-8	44
883	Rearrangement reactions of taxanes: structural modifications of 10-deacetylbaccatin III.. 1992 , 48, 6965-6974	50
882	Synthetic studies of taxane carbon framework. A highly efficient eight-membered ring cyclization with complete stereocontrol. 1992 , 48, 6975-6984	19
881	Toward the synthesis of the taxol C,D, ring system: Photolysis of β -methoxy ketones. 1992 , 48, 7033-7048	31
880	The chemistry of taxanes: unexpected rearrangement of baccatin III during chemoselective debenzoylation with Bu ₃ SnOMe/LiCl. 1992 , 33, 3979-3982	26
879	Galactose-Imines in the staudinger reaction. 1992 , 33, 2111-2114	28
878	Mixed acetoxy-benzoxy taxane esters from <i>Taxus brevifolia</i> . 1992 , 31, 4249-4252	19
877	Taxol: a novel radiation sensitizer. 1992 , 22, 613-7	252
876	cis-diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics. 1992 , 116, 146-51	33
875	Overview of new treatments for breast cancer. 1992 , 21, 3-13	28
874	Nerve growth factor prevents experimental cisplatin neuropathy. 1992 , 31, 76-80	236
873	Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. 1993 , 71, 1797-800	65
872	Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. 1993 , 71, 1571-80	90
871	High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. 1993 , 621, 231-8	89
870	Neurotoxicity of antineoplastic agents. 1993 , 14, 61-75	37
869	NMR and molecular modeling study of the conformations of taxol and of its side chain methylester in aqueous and non-aqueous solution.. 1993 , 49, 6545-6560	105

- 868 New synthesis of a taxol A-ring system.. **1993**, 49, 2701-2710 11
- 867 The seven-membered ring intermediate to control the stereochemistry on the eight-membered taxane B ring cyclization. **1993**, 34, 345-348 11
- 866 Taxol structure-activity relationships: Synthesis and biological evaluation of 2-deoxytaxol. **1993**, 34, 3205-3206 44
- 865 A facile synthesis of 7,10-dideoxy taxol and 7-epi-10-deoxy taxol. **1993**, 34, 6845-6848 15
- 864 Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. **1993**, 32, 235-42 226
- 863 Novel water soluble phosphate prodrugs of taxol possessing in vivo antitumor activity. **1993**, 3, 1761-1766 60
- 862 Synthesis and antitumor evaluation of water soluble taxol phosphates. **1993**, 3, 1357-1360 73
- 861 Studies toward structure-activity relationships of taxol : synthesis and cytotoxicity of taxol analogues with C-2? modified phenylisoserine side chains. **1993**, 3, 2471-2474 47
- 860 Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. **1993**, 68, 1104-9 295
- 859 An intramolecular diels-alder approach to tricyclic taxoid skeletons. **1993**, 34, 3367-3370 31
- 858 Wide QRS rhythm due to taxine toxicity. **1993**, 4, 59-61 9
- 857 Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. **1993**, 10, 743-9 171
- 856 Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. **1993**, 119, 727-33 83
- 855 Optimal versus maximally tolerated dose in cancer chemotherapy treatment. **1993**, 119, 576-7 2
- 854 Taxol metabolism in rat hepatocytes. **1993**, 46, 1661-4 27
- 853 The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. **1993**, 233, 177-8 45
- 852 An enzyme immunoassay for the determination of taxol and taxanes in Taxus sp. tissues and human plasma. **1993**, 158, 5-15 65
- 851 Chapter 32. Taxol: From Discovery to Therapeutic Use. **1993**, 305-314 70

850	Taxol and taxane production by <i>Taxomyces andreanae</i> , an endophytic fungus of Pacific yew. 1993 , 260, 214-6	1228
849	Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. 1993 , 32, 2747-55	374
848	An overview of experience with TAXOL (paclitaxel) in the U.S.A. 1993 , 19 Suppl C, 63-78	64
847	Taxol and taxotere--current status and future prospects. 1993 , 29A, 1228-31	22
846	Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group. 1993 , 19 Suppl C, 79-86	22
845	Chemotherapy for ovarian cancer. 1993 , 29A, 632-5	5
844	Taxol formation in yew <i>Taxus</i> . 1993 , 92, 1-12	29
843	Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report. 1993 , 698, 398-402	1
842	Evaluation of taxol cardiotoxicity in metastatic breast cancer. 1993 , 698, 403-5	5
841	The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). 1993 , 19, 351-86	234
840	Simple Bench-Top Bioassays (Brine Shrimp and Potato Discs) for the Discovery of Plant Antitumor Compounds. 1993 , 112-137	23
839	Abstracts. 1993 , 11, 1-59	
838	New cytostatic drugs in ovarian cancer. 1993 , 4 Suppl 4, 63-70	19
837	Role of Plants in the National Cancer Institute Drug Discovery and Development Program. 1993 , 80-95	17
836	CEPHALOMANNINE AND 10-DEACETYLTAXOL CYTOTOXICITY IN HUMAN GLIAL AND NEUROBLASTOMA CELL-LINES. 1993 , 2, 297	1
835	SYSTEMIC TREATMENT OF ADVANCED MALIGNANT-MELANOMA (REVIEW). 1993 , 2, 245	
834	Response. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 674-676	9.7 3
833	Determination of Taxol in <i>Taxus Media</i> Needles in the Presence of Interfering Components. 1993 , 16, 723-731	34

832	Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 384-8	9-7	359
831	Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. 1993 , 11, 2127-35		252
830	Overview of paclitaxel (TAXOL). 1993 , 9, 2-5		23
829	Crystal Structure of (5RS,6RS,10RS,11RS)-5,6,10,11-Tetrahydro-5-acetyl-8-formyl-10-hydroxy-4,11-dimethoxy-7,7,9-trimethyl-6,10-methano- 1993 , 9, 433-434		
828	Diastereoselective Conjugate Addition for Construction of Taxane Precursors. 1993 , 22, 1279-1282		3
827	Paclitaxel (TAXOL): side effects and patient education issues. 1993 , 9, 6-10		29
826	Taxol in ovarian cancer. 1993 , 71, 1591-6		45
825	Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. 1993 , 4, 321-4		23
824	Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. 1993 , 4, 151-5		23
823	Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?. 1993 , 4, 471-4		2
822	The Discovery and Development of New Antileukemic Drugs. 1993 , 7, 233-254		
821	The experience of a single Australian paediatric oncology unit. 1993 , 159, 453-458		1
820	Role of High-Dose Chemotherapy and Autologous Stem Cell Support in Treatment of Breast Cancer. 1993 , 7, 631-645		10
819	Paclitaxel (Taxol) in Breast Cancer. 1994 , 8, 121-140		26
818	[Quantitative determination of dose-response relations of taxol and cisplatin in ovarian cancer cells with a bioassay in comparison with cytomorphology]. 1994 , 34, 79-86		
817	Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. 1994 , 12, 1458-67		127
816	Summary. 1994 , 28, S31-S34		1
815	The discovery of drugs from higher plants. 1994 , 26, 81-108		17

814	Taxol arrests the development of blood-stage Plasmodium falciparum in vitro and Plasmodium chabaudi adami in malaria-infected mice. 1994 , 94, 413-7	46
813	Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. 1994 , 12, 241-8	113
812	Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. 1994 , 12, 2277-83	159
811	Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report. 1994 , 11, 309-18	23
810	Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. 1994 , 24, 6-14	71
809	Factors affecting the in vitro rapid germination of Taxus embryos and the evaluation of taxol content in the plantlets. 1994 , 39, 261-263	25
808	A chemoselective approach to functionalize the C-10 position of 10-deacetylbaccatin III. Synthesis and biological properties of novel C-10 Taxol analogues. 1994 , 35, 5543-5546	31
807	Partial synthesis of major human metabolites of docetaxel. 1994 , 50, 10289-10298	15
806	Synthesis of new taxoids. 1994 , 50, 9649-9656	14
805	Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. 1994 , 6, 40-8	55
804	Solvent- and concentration-dependent molecular interactions of taxol (Paclitaxel). 1994 , 83, 1470-6	49
803	Synthesis of carbon-14 labeled Taxol (paclitaxel). 1994 , 34, 973-980	7
802	New chemotherapeutic agents for breast cancer. 1994 , 74, 1164-76	17
801	Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules. 1994 , 74, 1377-82	46
800	Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. 1994 , 74, 1891-8	18
799	Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. 1994 , 37, 839-45	58
798	Chemistry and Biology of Taxol. 1994 , 33, 15-44	526
797	Chemie und Biologie von Taxol. 1994 , 106, 38-69	104

796	Synthesis of (2R, 3S)-methyl-2-fluoro-3-(n-benzoylamino)-3-phenylpropanoate: Modified side chain of taxol. 1994 , 5, 955-960	45
795	N-benzoyl-(2R,3S)-3-phenylisoserine methyl ester; a facile and convenient synthesis and resolution by entrainment. 1994 , 5, 1683-1688	15
794	Structure-activity relationships of taxol : synthesis and biological evaluation of C2 taxol analogs. 1994 , 4, 479-482	43
793	Reversed-phase high-performance liquid chromatographic determination of taxol in mouse plasma. 1994 , 655, 315-9	47
792	Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. 1994 , 53, 111-22	71
791	On the reaction of taxol with DAST. 1994 , 35, 41-44	28
790	Highlight on the studies of anticancer drugs derived from plants in China. 1994 , 12, 53-63	138
789	Taxol and embryonic development in the chick. 1994 , 14, 23-30	8
788	Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. 1994 , 120, 754-7	30
787	Novel taxol formulations: preparation and characterization of taxol-containing liposomes. 1994 , 11, 889-96	172
786	Synthesis and antitumor evaluation of 2?-oxycarbonylpaclitaxels (paclitaxel-2?-carbonates). 1994 , 4, 1861-1864	25
785	Total synthesis of taxol. 1994 , 367, 630-4	868
784	Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. 1994 , 85, 1057-62	19
783	Clinical pharmacokinetics of paclitaxel. 1994 , 27, 256-69	115
782	Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. 1994 , 33, 441-4	95
781	Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. 1994 , 34, 465-71	115
780	Comparative effects of taxol and Taxotere on two different human carcinoma cell lines. 1994 , 34, 335-43	45
779	Bullatacin--in vivo and in vitro experience in an ovarian cancer model. 1994 , 34, 166-70	21

778	The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. 1994 , 33, 331-9	94
777	Drug-induced pulmonary disease. 1994 , 40, 253-310	37
776	Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. 1994 , 48, 1265-72	93
775	Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. 1994 , 640, 195-204	63
774	Taxol protects against calcium-mediated death of differentiated rat pheochromocytoma cells. 1994 , 55, 313-9	19
773	Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. 1994 , 30A, 691-6	24
772	Taxol. 1994 , 45, 663-674	29
771	Overview of Paclitaxel Research. 1994 , 1-17	5
770	Primary therapy of multiple myeloma with paclitaxel (taxol). 1994 , 5, 757-9	19
769	Abstracts. 1994 , 12, 1-64	15
768	Pharmacology and Antitumor Effect of Novel Paclitaxel Formulations. 1994 , 111-123	7
767	Paclitaxel (taxol). 1994 , 14, 3-34	77
766	Use of Taxol (paclitaxel) in breast cancer. 1994 , 51 Suppl 1, 29-32	13
765	Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. 1994 , 69, 299-306	102
764	Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. 1994 , 51 Suppl 1, 33-9	2
763	Effect of the microtubule-disrupting drug colchicine on rat cerulein-induced pancreatitis in comparison with the microtubule stabilizer taxol. <i>Pancreas</i> , 1995 , 11, 294-302	2.6 10
762	7 The biochemical pharmacology of taxol and mechanisms of resistance. 1995 , 301-335	8
761	Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. 1995 , 115, 340-4	35

760	Taxol and its related taxoids from the needles of <i>Taxus sumatrana</i> . 1995 , 43, 365-7	10
759	Paclitaxel-induced neuropathy. 1995 , 6, 489-94	191
758	How does taxol stabilize microtubules?. 1995 , 5, 900-8	190
757	Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. 1995 , 84, 1223-30	141
756	Fermentation and isolation of C10-deacetylase for the production of 10-deacetylbaccatin III from baccatin III. 1995 , 48, 547-50	14
755	Antiproliferative activity of taxol on human tumor and normal breast cells vs. effects on cardiac cells. 1995 , 60, 571-5	8
754	Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa. 1995 , 32, 1381-9	37
753	Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). 1995 , 13, 1-11	38
752	Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail <i>Lymnaea stagnalis</i> . 1995 , 25, 49-57	18
751	A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. 1995 , 13, 217-22	18
750	The distribution of systemically administered [³ H]-paclitaxel in rats: a quantitative autoradiographic study. 1995 , 37, 173-8	38
749	Paclitaxel metabolites in human plasma and urine: identification of 6 alpha-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. 1995 , 9, 495-502	34
748	Concentrations of taxol and related taxanes in the needles of different <i>Taxus</i> cultivars. 1995 , 6, 149-156	19
747	Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. 1995 , 86, 1203-9	64
746	Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research. 1995 , 1, 128-154	1
745	Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. 1995 , 664, 383-91	60
744	The pinene path to taxol: Readily accessible a-ring building blocks based on novel alkyl- and alkenyllithium reagents with internal carbonyl groups. 1995 , 36, 7181-7184	11
743	Conformational analysis of c3?-c8 connected biflavones. 1995 , 32, 1531-1535	9

742	Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. 1995 , 13, 1714-9	52
741	Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. 1995 , 13, 583-7	38
740	Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. 1995 , 13, 2066-71	60
739	Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 676-81	9-7 103
738	3 Paclitaxel (taxol [®]) formulation and prodrugs. 1995 , 103-130	11
737	Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. 1995 , 31A, 230-7	36
736	Preclinical pharmacology of docetaxel. 1995 , 31A Suppl 4, S1-6	59
735	Influence of various concentrations of taxol on cell survival, micronuclei induction, and LDH activity in cultured V79 cells. 1995 , 96, 195-200	18
734	Tumor cell growth inhibition by several Annonaceous acetogenins in an in vitro disk diffusion assay. 1995 , 96, 55-62	77
733	Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. 1995 , 21, 463-78	53
732	Resistance against ethacrynic acid in glutathione transferase 7-7 (GST-P)-positive hepatocytes isolated from carcinogen-treated rats: the role of cytoskeletal changes and ATP depletion. 1995 , 9, 937-43	2
731	Paclitaxel (taxol). 1995 , 332, 1004-14	1703
730	Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. 1995 , 36, 299-304	45
729	Effects of Taxol on choriocarcinoma cells. 1995 , 173, 1835-42	14
728	Taxanes: a new class of antitumor agents. 1995 , 13, 381-404	218
727	Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. 1995 , 36, 385-92	54
726	Taxol encapsulation in poly(epsilon-caprolactone) microspheres. 1995 , 36, 279-82	76
725	Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. 1995 , 36, 227-232	9

724	Novel Strategies for Plant-Derived Anticancer Agents. 1995 , 33, 48-58	12
723	Paclitaxel and docetaxel. Innovation, but at what cost?. 1995 , 8, 1-4	1
722	The anti-tumor agent, taxol, attenuates contractile activity in rat aortic smooth muscle. 1995 , 56, PL157-61	5
721	Paclitaxel: a unique tubulin interacting anticancer agent. 1995 , 32, 289-337	26
720	Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). 1995 , 88, 73-9	83
719	Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. 1995 , 12 Suppl 2, S107-15	7
718	Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. 1995 , 12 Suppl 1, S163-72	33
717	Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. 1996 , 156, 1606-8	78
716	Section Review; Anti-infectives: Review of actinomycetes compounds 1990 □ 1995. 1996 , 5, 207-223	27
715	Taxol partitioning in two-phase plant cell cultures of <i>Taxus brevifolia</i> . 1996 , 49, 95-100	34
714	Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer. 1996 , 36, 168-70	4
713	Taxol production in nodule cultures of <i>Taxus</i> . 1996 , 59, 246-50	33
712	Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. 1996 , 32A, 226-30	51
711	Single agent paclitaxel in advanced squamous cell head and neck carcinoma. 1996 , 32A, 901-2	19
710	Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. 1996 , 32A, 1822-3	9
709	The effects of taxol, methylprednisolone, and 4-aminopyridine in compressive spinal cord injury: a qualitative experimental study. 1996 , 46, 350-7	24
708	Abstracts. 1996 , 14, 1-73	
707	Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. 1996 , 39, 424-31	224

706	Emerging drug treatments for solid tumours. 1996 , 51, 45-72	14
705	Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy. 1996 , 35, 733-6	5
704	In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel. 1996 , 40, 358-61	18
703	Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. 1996 , 14, 1993-9	69
702	Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. 1996 , 14, 792-5	185
701	Actin microfilament disrupters enhance K(ATP) channel opening in patches from guinea-pig cardiomyocytes. 1996 , 492 (Pt 2), 395-404	89
700	Fatal myocardial infarction potentially induced by paclitaxel. 1996 , 30, 1110-2	8
699	Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?. 1996 , 14, 498-500	2
698	Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel--a case report. 1996 , 178, 331-7	2
697	Phase II study of paclitaxel in patients with recurrent malignant glioma. 1996 , 14, 2316-21	77
696	Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development. 1996 , 1, 183-98	1
695	Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients. 1996 , 3, 162-8	18
694	Treatment of mice with a novel antineoplastic agent taxol before irradiation increases the frequency of micronuclei in the bone marrow. 1996 , 349, 219-27	8
693	Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. 1996 , 355, 103-28	14
692	Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. 1996 , 19, 115-130	105
691	Promising new agents in the treatment of non-small cell lung cancer. 1996 , 37, 385-93	37
690	In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines. 1996 , 77, 1940-6	18
689	An efficient synthesis of cis-3-hydroxy-4-phenyl-lactams: Precursor for taxol side chain. 1996 , 52, 5585-5590	34

688	Taxanes from the bark of <i>Taxus brevifolia</i> . 1996 , 41, 863-866	14
687	Taxanes of the needles of <i>Taxus x media</i> . 1996 , 43, 439-442	13
686	Supercritical fluid extraction of paclitaxel and baccatin III from needles of <i>taxus cuspidata</i> . 1996 , 9, 192-198	19
685	Production of taxanes by <i>Taxus baccata</i> plant cells. 1996 , 18, 501-504	3
684	Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients. 1996 , 27, 241-50	9
683	New microtubular agents in pediatric oncology. 1996 , 14, 49-54	9
682	Paclitaxel (Taxol)--a guide to administration. 1996 , 5, 147-52	10
681	Methyl jasmonate-induced overproduction of paclitaxel and baccatin III in <i>Taxus</i> cell suspension cultures. 1996 , 14, 1129-32	370
680	Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. 1996 , 74, 1668-73	12
679	A Large Scale Process for Paclitaxel and other Taxanes from the Needles of <i>Taxus x Media Hicksii</i> and <i>Taxus Floridana</i> Using Reverse Phase Column Chromatography. 1996 , 19, 427-447	19
678	An alternative to DEHP plasticized polyvinyl chloride in chemotherapy drug delivery systems. 1996 , 2, 314-320	5
677	A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. 1996 , 7, 165-71	74
676	Antagonism of paclitaxel cytotoxicity by X-rays. 1996 , 8, 991-6	4
675	Review : Pharmacokinetics and pharmacodynamics of the taxanes. 1997 , 3, 76-93	10
674	Lipid-laden macrophage infiltration of human adenocarcinoma in vivo associated with taxol and GCSF treatment. 1997 , 15, 18-22	2
673	Synthesis of Water-Soluble Paclitaxel Derivatives by Enzymatic Acylation. 1997 , 119, 11554-11555	77
672	Synthesis and Reactions of 3-(Nosyloxy)-2-keto Esters. 1997 , 62, 2458-2465	14
671	Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. 1997 , 33, 1393-9	60

670	Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. 1997 , 33, 1291-8	56
669	A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. 1997 , 33, 1699-702	26
668	The Emerging Role of Paclitaxel and Carboplatin in Non-Small Cell Lung Carcinoma. 1997 , 29, 73-90	1
667	Acute tumor lysis syndrome associated with paclitaxel. 1997 , 31, 1548-9	12
666	GML sensitizes cancer cells to Taxol by induction of apoptosis. 1997 , 15, 1369-74	20
665	Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. 1997 , 75, 1744-52	73
664	Liposomal delivery system for taxol. 1997 , 83, 87-90	20
663	In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. 1997 , 49, 157-166	50
662	Local delivery of chemotherapy: a supplement to existing cancer treatments. A case for surgical pastes and coated stents. 1997 , 26, 199-207	28
661	Taxol effect: bizarre mitotic figures (abnormal spindle asters) in a malignant peritoneal effusion: report of a case. 1997 , 17, 209-12	10
660	A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. 1997 , 67, 137-40	47
659	Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. 1997 , 67, 131-6	37
658	Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. 1997 , 35, 47-53	148
657	Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. 1997 , 18, 73-9	23
656	Synthesis of novel taxol analogs and evaluation of their biological activities. 1997 , 7, 1941-1944	11
655	Miniaturized HPLC and ionspray mass spectrometry applied to the analysis of Paclitaxel and taxanes. 1997 , 15, 1729-39	17
654	Synthesis of enantiomerically pure desmethyl C,D-ring derivative of paclitaxel (taxolTM) via asymmetric Diels-Alder reaction of 2-siloxyfuran. 1997 , 38, 2725-2728	12
653	Semi-synthesis of paclitaxel from naturally occurring glycosidic precursors. 1997 , 34, 675-680	10

652	Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. 1997 , 56, 305-10	26
651	Synthesis of novel 3'-trifluoromethyl taxoids through effective kinetic resolution of racemic 4-CF ₃ -beta-lactams with baccatins. 1997 , 9, 487-94	34
650	Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. 1997 , 79, 1022-30	10
649	Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. 1997 , 70, 297-301	26
648	Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. 1997 , 72, 844-50	47
647	Potentialiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells. 1998 , 89, 970-6	13
646	New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). 1998 , 77 Suppl 2, 29-37	33
645	Development of a fluorescence polarization immunoassay (FPIA) for the quantitative determination of paclitaxel. 1998 , 212, 1-7	10
644	Activity of lysosomal system in mouse liver after taxol administration. 1998 , 30, 239-43	6
643	Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. 1998 , 82, 2270-2274	150
642	Schedule-dependent interaction of paclitaxel (Taxol) and irradiation in vitro. 1998 , 6, 10-7	4
641	Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development. 1998 , 18, 315-31	135
640	Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro. 1998 , 174, 37-42	7
639	Malignant transformation alters intracellular trafficking of lysosomal cathepsin D in human breast epithelial cells. 1998 , 4, 283-96	24
638	Taxanes from the bark of <i>Taxus brevifolia</i> . 1998 , 47, 1315-1324	6
637	Pharmaceutical aspects of paclitaxel. 1998 , 172, 1-15	172
636	Paclitaxel reduces anti-dsDNA antibody titer and BUN, prolonging survival in murine lupus. 1998 , 20, 669-77	12
635	Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. 1998 , 40, 661-6	36

634	Enhancement of radiation response by paclitaxel in mice according to different treatment schedules. 1998 , 40, 1163-70	14
633	Taxol-DNA interactions: fluorescence and CD studies of DNA groove binding properties of taxol. 1998 , 1381, 104-12	93
632	CANCER CHEMOTHERAPY AND THE LIVER. 1998 , 2, 631-642	2
631	Paclitaxel-Induced Modification of the Effects of Radiation and Alterations in the Cell Cycle in Normal and Tumor Mammalian Cells. 1998 , 150, 283	14
630	Microtubule disruption potentiates phenylephrine-induced vasoconstriction in rat mesenteric arterial bed. 1998 , 351, R1-3	22
629	Cytotoxic and genotoxic effects of paclitaxel (Taxol) and radiation in a squamous cell carcinoma cell line of the larynx. 1998 , 118, 600-5	7
628	Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. 1998 , 32, 97-106	2
627	Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. 1998 , 273, 30777-84	177
626	Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. 1998 , 273, 18984-91	179
625	Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma. 1998 , 16, 314-8	8
624	New active paclitaxel glucuronide derivative with improved water solubility.. 1998 , 12, 391	2
623	Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. 1998 , 13, 839-48	20
622	Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. 1998 , 55, 228-34	9
621	Cytostatic drugs. 1998 , 21, 463-474	
620	Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study. 1998 , 21, 310-314	
619	Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. 1998 , 44, 129-34	25
618	In vitro cytotoxicity of paclitaxel-transferrin conjugate on H69 cells. 1998 , 5, 1381-3	7
617	Liposomes as carriers of lipophilic antitumor agents. 1998 , 283-296	1

616	Taxol-Induced Apoptosis May Occur Via a Signaling Pathway Independent of Microtubule Bundling and Cell Cycle Arrest. 1998 , 4, 1042-1043	4
615	Experience with new chemotherapeutic agents in non-small cell lung cancer. 1998 , 113, 32S-39S	16
614	Microtubules are involved in early hypertrophic responses of myocardium during pressure overload. 1998 , 275, H341-8	19
613	Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. 1999 , 17, 1876-83	159
612	Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. 1999 , 17, 1132	61
611	Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents. 1999 , 4, 17-33	33
610	A common pharmacophore for cytotoxic natural products that stabilize microtubules. 1999 , 96, 4256-61	241
609	Diels-Alder approach towards the stereocontrolled construction of a taxol C ring fragment. 1999 , 55, 5185-5194	14
608	(iPrO) ₃ TiCl-induced reactions of β - and β (20)-epoxy-5-hydroxytriacetyltaxicin I. 1999 , 55, 12099-12108	5
607	Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. 1999 , 44, 407-12	40
606	Localized paclitaxel delivery. 1999 , 183, 85-100	102
605	A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells. 1999 , 17, 495-500	123
604	Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. 1999 , 80, 1052-7	29
603	Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. 1999 , 81, 416-22	88
602	In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. 1999 , 81, 1318-27	187
601	The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines. 1999 , 75, 194-7	10
600	Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. 1999 , 54, 165-71	2
599	Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. 1999 , 17, 187-92	4

598	Taxol-induced meiotic maturation delay, spindle defects, and aneuploidy in mouse oocytes and zygotes. 1999 , 423, 79-90	46
597	Complexation and ionophoric properties of taxol and colchicine: complex formation and transport of sodium, potassium, magnesium and calcium ions across a liquid membrane. 1999 , 7, 179-85	2
596	Evaluation of the genotoxic activity of paclitaxel by the in vitro micronucleus test in combination with fluorescent in situ hybridization of a DNA centromeric probe and the alkaline single cell gel electrophoresis technique (comet assay) in human T-lymphocytes. 1999 , 34, 269-78	57
595	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. 1999 , 86, 1251-7	20
594	INVESTIGATIONS ON PREPARATIVE THIN-LAYER CHROMATOGRAPHIC SEPARATION OF TAXOIDS FROM TAXUS BACCATA L.. 1999 , 22, 2483-2502	16
593	Induction of geranylgeranyl diphosphate synthase activity and taxane accumulation in <i>Taxus baccata</i> cell cultures after elicitation by methyl jasmonate. 1999 , 147, 1-8	38
592	Combination of paclitaxel and radiation: genotoxicity in vitro in four mammalian cell lines. 1999 , 145, 29-33	6
591	Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. 1999 , 26, 281-90	7
590	A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. 1999 , 20, 403-25	24
589	A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 1999 , 56, 267-73	3
588	A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma. 2000 , 11, 409-13	31
587	Rapid and sensitive determination of paclitaxel (Taxol(R)) in environmental samples by high-performance liquid chromatography tandem mass spectrometry. 2000 , 14, 930-5	14
586	Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. 2000 , 44, 156-63	52
585	Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. 2000 , 89, 431-6	66
584	Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. 2000 , 89, 983-994	104
583	Development of a fluorescence immunoassay for measurement of paclitaxel in human plasma. 2000 , 283, 33-8	17
582	Screening for pharmaceutically important taxoids in <i>Taxus baccata</i> var. <i>Aurea</i> corr. with CC/SPE/HPLC-PDA procedure. 2000 , 14, 516-29	13
581	Novel Dimeric Taxoids via Highly Regio- and Stereospecific Diels-Alder Cycloadditions of Taxinine B and Taxicine I Derivatives. 2000 , 56, 1181-1192	5

580	The Synthesis and Biological Activity of 9- and 2?-cAMP 7-Deoxypaclitaxel Analogues from 5-Cinnamoyltriacetyltaxicin-I. 2000 , 56, 1667-1679	10
579	Synthesis and biological evaluation of novel 9-functional heterocyclic coupled 7-deoxy-9-dihydropaclitaxel analogue. 2000 , 10, 517-21	17
578	Interaction of taxol with human serum albumin. 2000 , 1478, 61-8	146
577	Novel signaling pathways contributing to vascular changes in hypertension. 2000 , 7, 431-43	24
576	Small guanosine triphosphatase Rho/Rho-associated kinase as a novel regulator of intracellular redistribution of lysosomes in invasive tumor cells. 2000 , 301, 341-51	16
575	Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells. 2000 , 4, 37-45	10
574	Bioactive Compounds from four Endophytic Penicillium sp. of a Northwest Pacific Yew Tree. 2000 , 24, 933-977	10
573	Novel combination chemotherapy in the treatment of non-small cell lung cancer. 2000 , 1, 1131-61	16
572	Molecular Microencapsulation: Paclitaxel Formations in Aqueous Medium Using Hydrophobized Poly(L-Lysine Citramide Imide). 2000 , 15, 99-114	8
571	Application of lipid as emulsifier in the solvent evaporation technique in fabrication of polymeric nanospheres for controlled release of Taxol.	
570	Molecular interactions between lipid and paclitaxel (Taxol/sup (R)/) within cell membrane simulated by the lipid monolayer at the air-water interface.	
569	An interesting observation of the position of some electronegative atoms in the taxol molecule. 2000 , 54, 172-6	2
568	Assessment of resistance to paclitaxel of murine tumors by (99m)Tc-MIBI/(201)Tl dual-radionuclide imaging. 2000 , 27, 127-33	3
567	Role of taxanes in adjuvant therapy. 2000 , 18, 32-8	4
566	A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. 2000 , 83, 458-62	102
565	Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. 2000 , 1, 136-43; discussion 144	6
564	Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. 2000 , 22, 263-302	468
563	Design and synthesis of paclitaxel-containing aminoester phosphate and phosphoamidate. 2001 , 11, 216-217	0

562	Colchicine and griseofulvin inhibit VCAM-1 expression on human vascular endothelial cells - evidence for the association of VCAM-1 expression with microtubules. 2001 , 25, 1-9	15
561	An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. 2001 , 121, 97-106	21
560	Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. 2001 , 122, 81-7	64
559	Microtubule structure at improved resolution. 2001 , 40, 8000-8	112
558	Factores pronósticos y quimioterapia de primera línea de los adenocarcinomas ováricos. 2001 , 37, 1-8	
557	p53 Signaling and cell cycle checkpoints. 2001 , 14, 243-63	171
556	Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. 2001 , 19, 1275-8	96
555	Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities. 2001 , 12, 117-28	29
554	Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 2001 , 23, 277-81	44
553	A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. 2001 , 24, 404-7	10
552	Selective drug resistant human osteosarcoma cell lines. 2001 , 259-67	18
551	Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. 2001 , 12, 1133-7	109
550	Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. 2001 , 8, 325-9	25
549	Diadenosine tetraphosphate-gating of cardiac K(ATP) channels requires intact actin cytoskeleton. 2001 , 364, 276-80	14
548	Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter. 2001 , 96, 275-82	43
547	Solid-phase extraction and simplified high-performance liquid chromatographic determination of 10-deacetylbaccatin III and related taxoids in yew species. 2001 , 26, 89-102	19
546	Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. 2001 , 11, 295-9	25
545	Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. 2001 , 53, 562-8	31

544	A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. 2001 , 91, 1543-8	98
543	Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. 2001 , 93, 139-41	19
542	Studies on the interaction of paclitaxel with tubulin by an electrochemical method. 2001 , 436, 147-152	10
541	Investigation of inclusion complexation of paclitaxel by cycloheptacosakis-(1-->2)-(beta-D-glucopyranosyl), by cyclic-(1-->2)-beta-D-glucans (cyclodextrins), and by cyclomaltoheptaoses (beta-cyclodextrins). 2001 , 334, 119-26	44
540	Chronic administration of single-agent paclitaxel in gynecologic malignancies. 2001 , 81, 201-5	17
539	Damaging effect of taxol on mouse spermatogenesis. 2001 , 132, 1087-92	9
538	Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. 2001 , 67, 223-33	25
537	Comparative molecular field analysis (coMFA) study of epothilones-tubulin depolymerization inhibitors: pharmacophore development using 3D QSAR methods. 2001 , 15, 41-55	23
536	Continuous-flow fluoro-immunosensor for paclitaxel measurement. 2001 , 16, 647-52	22
535	Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. 2001 , 9, 1967-76	44
534	Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. 2001 , 71, 53-69	334
533	In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. 2001 , 72, 191-202	585
532	Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer. 2001 , 2, 204-9	1
531	A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer. 2001 , 31, 482-7	3
530	Taxol. 2001 ,	
529	A feasibility study of paclitaxel 225 mg/m ² and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan. 2002 , 32, 48-53	7
528	The antineoplastic drug Paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. 2002 , 73, 216-23	15
527	IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. 2002 , 61, 105-13	55

526	A BRIEF HISTORY OF CANCER CHEMOTHERAPY. 2002 , 1-11	5
525	Dexamethasone prophylaxis for paclitaxel hypersensitivity. 2002 , 8, 81-87	3
524	Molecular Interactions between a Lipid and an Antineoplastic Drug Paclitaxel (Taxol) within the Lipid Monolayer at the Air/Water Interface. 2002 , 18, 4061-4070	49
523	Paclitaxel in cancer therapy. 2002 , 3, 755-66	237
522	Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. 2002 , 37, 189-99	12
521	Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC). 2002 , 38, 91-6	9
520	Proteasomal degradation of human peptidyl prolyl isomerase pin1-pointing phospho Bcl2 toward dephosphorylation. 2002 , 4, 218-27	31
519	Local erythematous dermatitis after intravenous docetaxel. 2002 , 53, 118-20	2
518	Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). 2002 , 3, 205-10; discussion 211-2	24
517	Noncovalent dimerization of paclitaxel in solution: evidence from electrospray ionization mass spectrometry. 2002 , 91, 2057-66	12
516	Stent-based antirestenotic coatings (sirolimus/paclitaxel). 2002 , 55, 404-8	34
515	Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines. 2002 , 97, 853-7	13
514	Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. 2002 , 100, 238-43	19
513	Combined modality radioimmunotherapy. Promise and peril. 2002 , 94, 1320-31	34
512	Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. 2002 , 25, 973-7	3
511	Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes. 2002 , 12, 1637-41	43
510	Interaction of paclitaxel with DSPC in monolayers at the air/water interface at different temperatures. 2002 , 25, 147-155	20
509	Paclitaxel and its formulations. 2002 , 235, 179-92	835

508	Investigation of genotoxic effect of taxol plus radiation on mice bone marrow cells. 2002 , 22, 1-11	4
507	Regio- and stereo-selective biotransformation of 25-O ¹⁴ C-tetra-acetoxy-4(20), 11-taxadiene by Ginkgo cell suspension cultures. 2002 , 58, 5659-5668	21
506	A stereocontrolled approach towards highly oxygenated taxane C and CD-ring precursors. 2002 , 43, 2757-2760	12
505	Synthesis and evaluation of water-soluble paclitaxel prodrugs. 2002 , 12, 3301-3	41
504	Monte Carlo docking simulations of cyclomaltoheptaose and dimethyl cyclomaltoheptaose with paclitaxel. 2002 , 337, 549-55	9
503	Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. 2002 , 19, 411-7	51
502	Isolation of differential genes in suspension cultures of <i>Taxus cuspidata</i> induced by additional taxol. 2002 , 20, 137-43	1
501	Microtubules, microtubule-interfering agents and apoptosis. 2003 , 8, 413-50	382
500	Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. 2003 , 82, 61-9	4
499	A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies. 2003 , 52, 277-81	7
498	Low-dose irradiation and short-exposure suboptimal-dose paclitaxel adversely modulate metastatic potential of squamous carcinoma cells. 2003 , 179, 812-8	6
497	Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma. 2003 , 6, 243-9	7
496	Spinal cord and peripheral nerve injury: current management and investigations. 2003 , 13, 322-32	20
495	First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. 2003 , 89, 354-9	16
494	Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model. 2003 , 91, 81-8	13
493	Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). 2003 , 98, 822-31	205
492	Platinum-based anticancer agents: innovative design strategies and biological perspectives. 2003 , 23, 633-55	279
491	A tubulin-based fluorescent polarization assay for paclitaxel. 2003 , 321, 44-9	10

490	Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. 2003 , 58, 4087-4114	278
489	Specific oxidation of C-14 oxygenated 4(20),11-taxadienes by microbial transformation. 2003 , 44, 1091-1094	16
488	Substrate specificity for the hydroxylation of polyoxygenated 4(20),11-taxadienes by Ginkgo cell suspension cultures. 2003 , 31, 345-56	6
487	An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. 2003 , 250, 45-50	60
486	Ephedrine derived reusable chiral auxiliary for the synthesis of optically pure 3-hydroxy-4-aryl-lactams. 2003 , 14, 453-459	21
485	Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. 2003 , 13, 287-91	10
484	Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress. 2003 , 88, 1649-58	20
483	Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. 2003 , 55, 1247-53	35
482	Investigation of structural requirements of anticancer activity at the paclitaxel/tubulin binding site using CoMFA and CoMSIA. 2003 , 21, 263-72	9
481	Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer. 2003 , 16, 471-475	4
480	Release of paclitaxel from polylactide-co-glycolide (PLGA) microparticles and discs under irradiation. 2003 , 20, 317-327	29
479	Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. 2003 , 68, 171-4	15
478	Alkaloids. 2003 ,	0
477	A paclitaxel-eluting stent for the prevention of coronary restenosis. 2003 , 348, 1537-45	376
476	Intraperitoneal taxanes. 2003 , 12, 825-33	49
475	Weekly paclitaxel infusion as salvage therapy in ovarian cancer. 2003 , 21, 675-81	12
474	Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. 2003 , 278, 23130-40	283
473	Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. 2003 , 33, 626-30	1

472	Chapter 15 Endocytotic events versus particle size: Multi-disciplinary analyses demonstrate L.C.M. sizes are mostly submicron. 2003 , 255-316	
471	Proteome analysis of differential protein expression in cervical cancer cells after paclitaxel treatment. 2004 , 36, 395-9	7
470	Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy. 2004 , 67, 385-407	10
469	Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. 2004 , 11, 413-24	255
468	Assessment of therapeutic tumor response using 99mtc-ethylenedicysteine-glucosamine. 2004 , 19, 443-56	26
467	Salvinal, a novel microtubule inhibitor isolated from <i>Salvia miltiorrhizae</i> Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells. 2004 , 65, 77-84	89
466	In vivo measurement of microtubule dynamics using stable isotope labeling with heavy water. Effect of taxanes. 2004 , 279, 49940-7	25
465	Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research. 2004 , 22, 331-7	3
464	Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. 2004 , 95, 506-12	22
463	Peroxidases during adventitious rooting in cuttings of <i>Arbutus unedo</i> and <i>Taxus baccata</i> as affected by plant genotype and growth regulator treatment. 2004 , 44, 257-266	48
462	Camptothecin-loaded films for the prevention of postsurgical adhesions. 2004 , 53, 355-62	24
461	Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. 2004 , 101, 1508-13	32
460	Molecular responses of vascular smooth muscle cells to paclitaxel-eluting bioresorbable stent materials. 2004 , 69, 513-24	15
459	Efficient purification and morphology characterization of paclitaxel from cell cultures of <i>Taxus chinensis</i> . 2004 , 79, 1162-1168	23
458	Amphiphilic dextran-graft-poly(epsilon-caprolactone) films for the controlled release of paclitaxel. 2004 , 271, 167-79	21
457	Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. 2004 , 275, 165-70	46
456	Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. 2004 , 280, 221-7	55
455	Paclitaxel-HSA interaction. Binding sites on HSA molecule. 2004 , 12, 3269-75	129

454	Human serum albumin: spectroscopic studies of the paclitaxel binding and proximity relationships with cisplatin and adriamycin. 2004 , 98, 1851-6	35
453	A large-scale purification of paclitaxel from cell cultures of <i>Taxus chinensis</i> . 2004 , 39, 1985-1991	67
452	Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study. 2004 , 5, 11-5	5
451	Tandem RCM of dienynes for the construction of taxol-type carbocyclic systems. 2004 , 6, 193-6	43
450	Correct diffusion coefficients of proteins in fluorescence correlation spectroscopy. Application to tubulin oligomers induced by Mg ²⁺ and Paclitaxel. 2004 , 87, 2635-46	66
449	Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. 2004 , 57, 313-8	115
448	Efficacy and Toxicity of Paclitaxel (Taxol) for the Treatment of Canine Malignant Tumors. 2004 , 18, 219-222	66
447	Mitochondrial organization and motility probed by two-photon microscopy in cultured mouse brainstem neurons. 2005 , 303, 114-27	56
446	Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. 2004 , 14, 63-6	45
445	Polymer Modification Of An Anti-Cancer Drug: Effects Of Hydrophilization. 2005 , 9, 13-14	5
444	Effects of absorbent treatment on the purification of paclitaxel from cell cultures of <i>Taxus chinensis</i> and yew tree. 2005 , 40, 1113-1117	41
443	Sensitive HPLC method for quantitation of paclitaxel (Genexol) in biological samples with application to preclinical pharmacokinetics and biodistribution. 2005 , 39, 170-6	56
442	Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. 2005 , 292, 149-56	46
441	Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. 2005 , 293, 303-10	32
440	Combined biotransformations of 4(20),11-taxadienes. 2005 , 61, 5507-5517	10
439	First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study. 2005 , 5, 151	18
438	Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. 2005 , 54, 468-76	24
437	Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. 2005 , 252, 1459-64	23

436	Enhanced bioavailability of paclitaxel by bamboo concentrate administration. 2005 , 28, 469-75	1
435	Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. 2005 , 22, 573-83	114
434	Ester Derivatives of Nucleoside Inhibitors of Reverse Transcriptase: 2. Molecular Systems for the Combined Therapy with 3?-Azido-3?-Deoxythymidine and 2?,3?-Didehydro-3?-Deoxythymidine. 2005 , 31, 405-418	1
433	Disruption of microtubular network attenuates histamine-induced dilation in rat mesenteric vessels. 2005 , 288, C443-9	8
432	Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. 2005 , 11, 3335-41	7
431	Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). 2005 , 11, 4136-43	380
430	Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. 2005 , 92, 1006-12	19
429	Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. 2005 , 11, 6669-77	15
428	Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. 2005 , 23, 7785-93	239
427	Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis. 2005 , 18, 461-478	1
426	Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. 2005 , 26, 623	3
425	Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines. 2005 , 26, 1563	2
424	A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. 2005 , 118, 23-34	88
423	Germ cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease. 2005 , 23, 293-302	2
422	Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. 2005 , 7, 957-66	13
421	Cardiotoxicity of cancer chemotherapy: implications for children. 2005 , 7, 187-202	118
420	Natural Products. 2005 , 11-72	5
419	Paclitaxel. 2006 , 2663-2669	

418	Terrestrial Plant-Derived Anticancer Agents and Plant Species Used in Anticancer Research. 2006 , 25, 79-113	58
417	Albumin-bound paclitaxel: a next-generation taxane. 2006 , 7, 1041-53	463
416	Synthesis of Biologically Active Heterocyclic Stilbene and Chalcone Analogs of Combretastatin. 1-51	26
415	Dose adaptation of antineoplastic drugs in patients with liver disease. 2006 , 29, 509-22	16
414	Design, total synthesis, and evaluation of novel open-chain epothilone analogues. 2006 , 8, 685-8	13
413	Inhibition of tumor metastasis in vivo by combination of paclitaxel and hyaluronic acid. 2006 , 243, 71-9	29
412	Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. 2006 , 42, 24-30	145
411	Therapeutic effect of paclitaxel and propolis on lipid peroxidation and antioxidant system in 7,12 dimethyl benz(a)anthracene-induced breast cancer in female Sprague Dawley rats. 2006 , 78, 2820-5	60
410	Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. 2006 , 12, 1412-5	52
409	Antitumor effects of IDN5109 on head and neck squamous cell carcinoma. 2006 , 15, 329	
408	Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. 2006 , 15, 621	1
407	Facteurs pronostiques et chimiothérapie de première ligne des adénocarcinomes ovariens. 2006 , 1, 1-8	
406	Characterization Of PEG-Modified Paclitaxel. 2006 , 10, 364-375	3
405	Characterization Of PEG-Modified Paclitaxel. 2006 , 10, lxxxviii-90	
404	The role of chemotherapy in the treatment of malignant astrocytomas. 2006 , 33, 127-40	11
403	Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. 2006 , 29, 246-51	7
402	Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface. 2006 , 20, 2183-9	26
401	Large-scale purification of 13-dehydroxybaccatin III and 10-deacetylpaclitaxel, semi-synthetic precursors of paclitaxel, from cell cultures of <i>Taxus chinensis</i> . 2006 , 1123, 15-21	27

400	A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer. 2006 , 57, 736-40	14
399	Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). 2006 , 103, 67-71	7
398	Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. 2006 , 33, 15-49	268
397	Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. 2006 , 32, 237-44	96
396	Production of paclitaxel and the related taxanes by cell suspension cultures of Taxus species. 2006 , 7, 453-61	64
395	Potential use of the adenosine triphosphate cell viability assay in endometrial cancer. 2006 , 13, 518-22	2
394	Production of Paclitaxel in Plant Cell Cultures. 515-528	
393	Physical and chemical stability of paclitaxel infusions in different container types. 2006 , 12, 211-22	16
392	Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. 2006 , 12, 1317-24	878
391	mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. 2006 , 12, 854-9	138
390	Weekly administration of paclitaxel induces long-term aneugenicity in nude mice. 2007 , 6, 377-82	7
389	Novel Local Treatment with Paclitaxel-Loaded Hydroxyapatite-Alginate Gels for Spinal Bone Metastases. 2007 , 330-332, 1343-1346	6
388	Antitumor Alkaloids in Clinical Use or in Clinical Trials. 25-52	0
387	Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. 2007 ,	6
386	The unusual suspects: a surprise regarding reactions to omalizumab. 2007 , 28, 259-61	18
385	Chemotherapy and delivery in the treatment of primary brain tumors. 2007 , 2, 197-211	9
384	Molecular modes of action of cytotoxic alkaloids: from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance. 2007 , 64, 1-47	44
383	Purification of Paclitaxel Isolated from Taxus baccata L. Cell Culture by Microwave-Assisted Extraction and Two-Dimensional Liquid Chromatography. 2007 , 31, 382-394	10

382	Layer by Layer Self-Assembly of Immunoglobulins for Piezoelectric Biosensors. 2007 ,	
381	Preparation and Dissolution Profiles of the Amorphous, Dihydrated Crystalline, and Anhydrous Crystalline Forms of Paclitaxel. 2007 , 25, 1759-1767	9
380	Nanosized paclitaxel particles from supercritical carbon dioxide processing and their biological evaluation. 2007 , 23, 2674-9	30
379	Nanostructured thin films for the development of piezoelectric immunosensors. 2007 , 2007, 2257-60	
378	Paclitaxel: a review of adverse toxicities and novel delivery strategies. 2007 , 6, 609-21	281
377	Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. 2007 , 2, 333-44	45
376	Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. 2007 , 13, 345-57	38
375	Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. 2007 , 2, 415-23	134
374	Paclitaxel. 2007 , 1-5	1
373	Dienyne ring-closing metathesis approach for the construction of taxosteroids. 2007 , 13, 5135-50	23
372	A Quantitative Investigation of the Water-Solubilizing Properties of Branched Oligoglycerols. 2007 , 2007, 3003-3011	12
371	Synthesis of 2'-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells. 2007 , 17, 617-20	40
370	A novel trans-lymphatic drug delivery system: implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres. 2007 , 28, 3236-44	75
369	Evaluation of paclitaxel rearrangement involving opening of the oxetane ring and migration of acetyl and benzoyl groups. 2007 , 43, 1141-5	8
368	Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel. 2007 , 7, 7	2
367	A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. 2007 , 97, 170-6	235
366	Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. 2007 , 16, 231-7	40
365	Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. 2007 , 34, 473-6	21

364	The effect of antisense oligodeoxynucleotides targeting Aurora A kinase on cell proliferation and chemosensitivity to paclitaxel in human lung cancer cell line A549. 2007 , 6, P258-P263	2
363	Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. 2008 , 29, 1233-41	172
362	Adjuvant chemotherapy in breast cancer. 2008 , 1, 91-98	1
361	Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. 2008 , 25, 274-8	13
360	Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. 2008 , 50, 699-700	7
359	Peripheral nerve damage associated with administration of taxanes in patients with cancer. 2008 , 66, 218-28	170
358	Natural products from plant cell cultures. 2008 , 329-370	5
357	Effects of pre-treating in vitro-matured bovine oocytes with the cytoskeleton stabilizing agent taxol prior to vitrification. 2008 , 75, 191-201	51
356	Protein nanoparticles as drug carriers in clinical medicine. 2008 , 60, 876-85	613
355	Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer. 2008 , 38, 1013-20	21
354	A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. 2008 , 98, 316-22	30
353	Drug Delivery and Medical Applications of Chemically Modified Hyaluronan. 2008 , 333-357	6
352	Natural Compounds as Drugs Volume I. 2008 ,	5
351	Checkpoint Responses in Cancer Therapy. 2008 ,	1
350	Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. 2008 , 197, 959-66	51
349	Neurologic Complications of Chemotherapy. 2008 , 287-326	6
348	Determination of Paclitaxel, 10-DAB, and Related Taxoids in Himalayan Yew Using Reverse Phase HPLC. 2008 , 13, 25-44	2
347	Highly efficient stereocontrolled synthesis of Danishefsky's taxol CD ring key intermediate. 2008 , 73, 6033-6	4

346	A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors. 2008 , 14, 3434-40	7
345	Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: A feasibility and pharmacokinetic study. 2008 ,	2
344	Paclitaxel in the management of ovarian cancer. 2008 , 3, 287-299	
343	Taxanes in the management of gynecologic malignancies. 2008 , 8, 219-26	5
342	Slow-releasing paclitaxel in polytetrafluoroethylene/poly(lactide-co-glycolide) laminate delays adjustment after strabismus surgery in rabbit model. 2008 , 49, 5340-5	3
341	Pharmacogenomics of importance for paclitaxel chemotherapy. 2008 , 9, 671-4	13
340	History of Liposomes. 2008 , 375-415	
339	In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. 2008 , 31, 1215-20	11
338	Drug eluting stents: friend or foe? A review of cellular mechanisms behind the effects of Paclitaxel and sirolimus eluting stents. 2008 , 9, 554-66	21
337	17 Systemic Chemotherapy. 2008 ,	
336	The role of Bcl-xL and nuclear factor-kappaB in the effect of taxol on the viability of dendritic cells. 2009 , 10, 99-103	4
335	Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. 2009 , 4, 99-105	357
334	HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. 2009 , 3, 3165-74	142
333	A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. 2009 , 30, 6006-16	185
332	In vitro and in vivo anticancer activity of 2-deacetoxytaxinine J and synthesis of novel taxoids and their in vitro anticancer activity. 2009 , 44, 3947-53	20
331	Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. 2009 , 27, 356-65	10
330	Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process. 2009 , 32, 139-48	21
329	Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. 2009 , 64, 87-94	15

328	Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. 2009 , 2, 2	68
327	Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. 2009 , 100, 1979-85	49
326	Morphology and in vitro release kinetics of drug-loaded micelles based on well-defined PMPC-b-PBMA copolymer. 2009 , 371, 190-6	41
325	Process utilized oligo-β-cyclodextrin substituted agarose gel medium for efficient purification of paclitaxel from <i>Taxus cuspidata</i> . 2009 , 68, 119-124	6
324	Paclitaxel release from micro-porous PLGA disks. 2009 , 64, 4341-4349	30
323	Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. 2010 , 28, 186-94	63
322	Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. 2009 , 155, 142-6	31
321	Supercritical Fluid Technology for Nanotechnology in Drug Delivery. 2009 , 69-104	5
320	Effect of unpurified Cremophor EL on the solution stability of paclitaxel. 2009 , 14, 1-8	13
319	Paclitaxel-Loaded Stabilizer-Free Poly(D,L-lactide-co-glycolide) Nanoparticles Conjugated with Quantum Dots for Reversion of Anti-Cancer Drug Resistance and Cancer Cellular Imaging. 2009 , 56, 923-934	11
318	Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. 2009 , 24, 418-27	35
317	Clinical studies with paclitaxel - eluting stent systems. 2010 , 16, 4025-36	3
316	Expression of taxol resistance gene 1 correlates with gastric cancer patient clinical outcome and induces taxol resistance. 2010 , 3, 1071-8	10
315	ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. 2005 , 57, 869-76	7
314	Enantioseparation of Aromatic α-Amino acid by Precolumn Derivatization with o-Phthaldialdehyde and N-Isobutyryl-L-cysteine. 2010 , 71, 1063-1067	9
313	Management of paclitaxel-induced neurotoxicity. 2010 , 4, 107-115	4
312	Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats. 2010 , 95, 331-7	39
311	Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. 1993 , 71, 594-600	36

310	Bioorthogonal Turn-On Probes for Imaging Small Molecules inside Living Cells. 2010 , 122, 2931-2934	123
309	Bioorthogonal turn-on probes for imaging small molecules inside living cells. 2010 , 49, 2869-72	327
308	The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. 2010 , 31, 5855-64	62
307	Heterogeneous and homogeneous nucleation of Taxol crystals in aqueous solutions and gels: effect of tubulin proteins. 2010 , 76, 199-206	10
306	Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1. 2010 , 10, 1	8
305	Near-infrared light triggers release of Paclitaxel from biodegradable microspheres: photothermal effect and enhanced antitumor activity. 2010 , 6, 1022-31	140
304	L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. 2010 , 101, 173-9	177
303	Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. 2010 , 17, 512-22	27
302	Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature. 2010 , 2010,	8
301	SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics. 2010 , 9, 2993-3002	17
300	Polymer prodrug approaches applied to paclitaxel. 2010 , 1, 778	35
299	Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel. 2002 , 54, 765-72	39
298	An unprecedented biogenetic-type chemical synthesis of 1(15-->11) abeotaxanes from normal taxanes. 2010 , 73, 747-50	2
297	Structural and biochemical studies of a fluoroacetyl-CoA-specific thioesterase reveal a molecular basis for fluorine selectivity. 2010 , 49, 9269-79	24
296	From taxuspine x to structurally simplified taxanes with remarkable p-glycoprotein inhibitory activity. 2010 , 1, 416-21	5
295	Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. 2010 , 36, 1377-87	36
294	Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel. 2011 , 12, 4395-413	48
293	Cellular uptake of ginsenosides in Korean white ginseng and red ginseng and their apoptotic activities in human breast cancer cells. 2011 , 77, 133-40	36

292	Potential of Negatively Charged Pectin Nanoparticles Encapsulating Paclitaxel: Preparation & Characterization. 2011,	2
291	Targeted Drug-Delivery Therapy of Tumors Using LCM. 2011, 25, 189-205	
290	A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. 2011, 74, 258-63	1
289	Paclitaxel-loaded polyester nanoparticles prepared by spray-drying technology: in vitro bioactivity evaluation. 2011, 28, 417-29	23
288	Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. 2011, 12, 228-34	80
287	PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. 2011, 300, 48-56	62
286	Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. 2011, 4, 123-36	50
285	Review of chemoradiotherapy for high-risk prostate cancer. 2011, 6, 64-8	6
284	An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in a rabbit graft model. 2011, 141, 1522-8	24
283	Solubility of Paclitaxel in Mixtures of Dichloromethane and Supercritical Carbon Dioxide. 2011, 19, 558-564	8
282	Synthesis of rotenoid derivatives with cytotoxic and topoisomerase II inhibitory activities. 2011, 21, 4813-8	20
281	Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury. 2011, 331, 928-31	414
280	Cytostatic and cytotoxic drugs. 2011, 33, 935-962	1
279	Potential of Complementary and Alternative Medicine in Preventive Management of Novel H1N1 Flu (Swine Flu) Pandemic: Thwarting Potential Disasters in the Bud. 2011, 2011, 586506	42
278	Paclitaxel as an anticancer agent: isolation, activity, synthesis and stability. 2011, 6, 527-536	7
277	Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts. 2011, 403, 130-5	5
276	Efficient purification of paclitaxel from yews using high-performance displacement chromatography technique. 2011, 1218, 2929-35	18
275	Effect of water content of organic solvent on microwave-assisted extraction efficiency of paclitaxel from plant cell culture. 2011, 28, 1561-1565	12

- 274 Establishment of a solvent map for formation of crystalline and amorphous paclitaxel by solvent evaporation process. **2011**, 28, 1918-1923 6
- 273 An improved high-performance liquid chromatography process for the large-scale production of paclitaxel. **2011**, 76, 378-384 6
- 272 Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. **2011**, 23, 59-66 55
- 271 The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. **2011**, 19, 382-90 44
- 270 A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. **2011**, 2011, 854872 23
- 269 Neurological complications of chemotherapy to the peripheral nervous system. **2012**, 105, 917-36 2
- 268 Development of NGR-based anti-cancer agents for targeted therapeutics and imaging. **2012**, 12, 76-86 28
- 267 Selection suitable solvents to prepare paclitaxel-loaded micelles by solvent evaporation method. **2012**, 17, 164-9 6
- 266 Nanomedicine: pharmacological perspectives. **2012**, 1, 12
- 265 Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. **2012**, 255, 140-6 14
- 264 Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. **2012**, 22, 498-507 21
- 263 Trimethyl lock: A trigger for molecular release in chemistry, biology, and pharmacology. **2012**, 3, 2412-2420 91
- 262 A facile semisynthesis of 2',7-bisacetyltaxol from 10-DABa. **2012**, 48, 702-703
- 261 Enhancing Taxol Biosynthesis by Overexpressing a 9-Cis-Epoxycarotenoid Dioxygenase Gene in Transgenic Cell Lines of *Taxus chinensis*. **2012**, 30, 1125-1130 17
- 260 Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure. **2012**, 38, 736-44 28
- 259 Identification of *Sedum kamschaticum*, *Lythrum anceps*, and *Astilbe chinensis* var. *dauidii* as inhibitors of peroxisome-proliferator-activated receptor α expression and lipid accumulation. **2012**, 55, 625-631
- 258 Epithelial Ovarian Cancer. **2012**, 285-328.e12 9
- 257 Determination of morphine, codeine, and paclitaxel in human serum and plasma by micellar electrokinetic chromatography. **2012**, 35, 2297-306 9

256	Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. 2012 , 3, 341-347	20
255	Effect of Process Parameters on Co-precipitation of Paclitaxel and Poly(L-lactic Acid) by Supercritical Antisolvent Process. 2012 , 20, 803-813	22
254	The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. 2012 , 7, e51458	58
253	Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. 2012 , 7, 6105-14	12
252	Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. 2012 , 30, 1132-7	8
251	Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. 2012 , 30, 1621-7	193
250	Development of self-immolative dendrimers for drug delivery and sensing. 2012 , 159, 154-63	42
249	Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. 2012 , 64, 775-82	10
248	Non-haematopoietic toxicity of anthracyclines is more favourable than that of taxanes: experience from Nairobi. 2012 , 4, 3-8	
247	Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. 2012 , 69, 523-31	14
246	Functional analysis of a WRKY transcription factor involved in transcriptional activation of the DBAT gene in <i>Taxus chinensis</i> . 2013 , 15, 19-26	67
245	Water-soluble paclitaxel by conjugation to hyperbranched polyglycidols. 2013 , 48, 5163-5170	1
244	The composition and end-group functionality of sterically stabilized nanoparticles enhances the effectiveness of co-administered cytotoxins. 2013 , 1, 1260-1272	17
243	Can controversial nanotechnology promise drug delivery?. 2013 , 113, 1686-735	160
242	Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. 2013 , 441, 701-11	97
241	Applications of Cyclic EGlucans. 2013 , 15-32	1
240	Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. <i>Molecular Pharmaceutics</i> , 2013 , 10, 3555-63	5.6 96
239	The winning formulation: the development of paclitaxel in pancreatic cancer. 2013 , 19, 5572-9	46

238	A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. 2013 , 19, 5210-7	22
237	Paclitaxel-induced neuropathic pain is age dependent and devolves on glial response. 2013 , 17, 75-85	37
236	The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance. 2013 , 109, 2131-41	9
235	Management of Paclitaxel-induced hand-foot syndrome. 2013 , 8, 215-7	7
234	Preclinical profile of cabazitaxel. 2014 , 8, 1851-67	45
233	A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. 2014 , 11, 479-87	16
232	Targeted Therapies in the Management of Breast Cancer. 2014 , 04,	
231	Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. 2014 , 10, e1004192	20
230	Expression of recombinant alpha and beta tubulins from the yew <i>Taxus cuspidata</i> and analysis of the microtubule assembly in the presence of taxol. 2014 , 78, 1887-94	4
229	Taxanes: impact on pancreatic cancer. 2014 , 25, 584-92	15
228	Taxanes as radiosensitizers. 2014 , 25, 502-11	15
227	The synthesis of novel taxoids for oral administration. 2014 , 22, 194-203	13
226	Improvement of hairy root cultures and plants by changing biosynthetic pathways leading to pharmaceutical metabolites: strategies and applications. 2014 , 32, 1168-79	41
225	Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. 2014 , 16, 114-24	24
224	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel. 2014 , 24, 855-9	7
223	EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma. 2014 , 35, 4133-45	53
222	Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. 2014 , 176, 76-85	76
221	Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations. 2014 , 35, 2264-71	115

220	Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. 2014 , 32, 89-96	28
219	Analyzing the Biological Entity of Nanomaterials: Characterization of Nanomaterial Properties in Biological Matrices. 2014 , 88-127	
218	Paclitaxel-loaded trimethyl chitosan-based polymeric nanoparticle for the effective treatment of gastroenteric tumors. 2014 , 32, 1481-8	22
217	PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase. 2015 , 5, 15666	9
216	Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin- α . 2015 , 156, 2184-2192	45
215	Paclitaxel and trastuzumab treatment affects insulin growth factor I expression in breast cancer cell lines. 2015 , 10, 799	
214	Dermatomyositis and Paclitaxel-Induced Cutaneous Drug Eruption Associated with Metastatic Breast Cancer. 2015 , 18, 195-9	3
213	Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. <i>Cancers</i> , 2015 , 7, 2360-71	6.6 143
212	The Role of Plants in the Drug Discovery Program of the United States National Cancer Institute. 2015 , 465-472	
211	Nanoformulations for therapy of pancreatic and liver cancers. 2015 , 10, 1515-34	5
210	Delivery of paclitaxel using PEGylated graphene oxide as a nanocarrier. 2015 , 7, 1355-63	118
209	Therapeutic potential of bryophytes and derived compounds against cancer. 2015 , 4, 236-248	28
208	Clinical Translation of Nanomedicine. 2015 , 115, 11147-90	494
207	A review of traditional use, phytoconstituents and biological activities of Himalayan yew, <i>Taxus wallichiana</i> . 2015 , 13, 80-90	24
206	Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. 2015 , 16, 8070-101	276
205	High tolerated paclitaxel nano-formulation delivered by poly (lactic-co-glycolic acid)-g-dextran micelles to efficient cancer therapy. 2015 , 11, 855-66	46
204	Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. 2015 , 29, 4461-72	53
203	Esophageal Squamous Cell Carcinoma. 2015 ,	2

202	Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy. 2015 , 32, 1002-16	58
201	Cytotoxic and immunosuppressant drugs. 2016 , 800-808	
200	Paclitaxel?. 2016 ,	2
199	Paclitaxel. 2016 , 445-452	
198	Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors. 2016 , 36, 399-409	18
197	Kinetics and thermodynamics of paclitaxel extraction from plant cell culture. 2016 , 33, 3175-3183	8
196	Enhanced Antiglioblastoma Efficacy of Neovasculature and Glioma Cells Dual Targeted Nanoparticles. <i>Molecular Pharmaceutics</i> , 2016 , 13, 3506-3517	5.6 20
195	Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis. 2016 , 8, 25753-25769	25
194	CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain. 2016 , 36, 11074-11083	110
193	Tc-tricarboxyl labeling of paclitaxel as an antimicrotubule agent and its evaluation in B16-F10 melanoma tumor-bearing mice. 2016 , 59, 582-588	1
192	Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. 2016 , 34, 750-759	24
191	Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles. 2016 , 509, 375-390	34
190	Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. 2016 , 56, 162-171	18
189	HPLC Method for the Dosage of Paclitaxel in Copaiba Oil: Development, Validation, Application to the Determination of the Solubility and Partition Coefficients. 2016 , 79, 405-412	8
188	Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. 2016 , 24, 1175-9	23
187	A pre-formulation study of a polymeric solid dispersion of paclitaxel prepared using a quasi-emulsion solvent diffusion method to improve the oral bioavailability in rats. 2016 , 42, 353-63	7
186	Investigation of graphene-based nanomaterial as nanocarrier for adsorption of paclitaxel anticancer drug: a molecular dynamics simulation study. 2017 , 23, 36	33
185	Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy. 2017 , 103, 149-153	24

184	Exploring β Tubulin Inhibitors from Plant Origin using Computational Approach. 2017 , 28, 230-241	9
183	Contemporary Oral Oncology. 2017 ,	5
182	Gambogic Acid-induced Autophagy and the MAPK Pathway in T98G Glioblastoma Cells. 2017 , 38, 1235-1237	
181	Effects of Hylomecon vernalis ethanol extracts on cell cycle and apoptosis of colon cancer cells. 2017 , 15, 3485-3492	3
180	Nanomedicine-based paclitaxel induced apoptotic signaling pathways in A562 leukemia cancer cells. 2017 , 149, 16-22	13
179	Actin and microtubule networks contribute differently to cell response for small and large strains. 2017 , 19, 093003	36
178	Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. 2017 , 12, 2129-2142	57
177	CHITOSAN MICROSPHERES FOR THE DELIVERY OF CHEMOTHERAPEUTIC AGENTS: PACLITAXEL AS A MODEL. 2017 , 10, 15	5
176	Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer. 2017 , 11, 768	17
175	Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. 2018 , 11, 426-435	14
174	Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics. 2018 , 45, 577-592	9
173	Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer. 2018 , 8, 602-614	39
172	Esophageal Adenocarcinoma. 2018 ,	1
171	Epithelial Ovarian Cancer. 2018 , 253-289.e14	0
170	Taxane Formulations: From Plant to Clinic. 2018 , 23-33	2
169	Neurotoxicity Related to Radiotherapy and Chemotherapy for Nonsmall Cell and Small Cell Lung Cancer. 2018 , 409-417.e2	
168	Characteristics, Properties and Analytical Methods of Paclitaxel: A Review. 2018 , 48, 110-118	44
167	Synthesis of CO ₂ -philic amphiphilic block copolymers by RAFT polymerization and its application on forming drug-loaded micelles using ScCO ₂ evaporation method. 2018 , 44, 13-18	4

166	JS-K enhances chemosensitivity of prostate cancer cells to Taxol via reactive oxygen species activation. <i>Oncology Letters</i> , 2019 , 17, 757-764	2.6	3
165	Taxanes for advanced non-small cell lung cancer. 2018 ,		78
164	Isotherm, Kinetic, and Thermodynamic Characteristics for Adsorption of 2,5-Xylenol onto Activated Carbon. 2018 , 23, 541-549		4
163	Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. 2018 , 14, 1744806918816462		26
162	Animal Model: Xenograft Mouse Models in Esophageal Adenocarcinoma. 2018 , 1756, 151-164		1
161	Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles. 2018 , 23, 561-569		16
160	RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers. 2018 , 26, 2019-2033		13
159	Novel resources of Taxol from endophytic and entomopathogenic fungi: Isolation, characterization and LC-Triple mass spectrometric quantification. 2018 , 190, 466-474		10
158	Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects. 2018 , 12, 40-52		20
157	Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery. 2018 , 151, 32-38		2
156	Nanoscale partitioning of paclitaxel in hybrid lipid-polymer membranes. 2018 , 143, 3808-3813		21
155	Chemometric approach to estimate kinetic properties of paclitaxel prodrugs and their substructures for solubility prediction through molecular modelling and simulation studies. 2019 , 33, e3181		1
154	Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. 2019 , 14, 1323-1341		44
153	A Novel Paclitaxel Conjugate with Higher Efficiency and Lower Toxicity: A New Drug Candidate for Cancer Treatment. 2019 , 20,		5
152	Predicting Paclitaxel Disposition in Humans With Whole-Body Physiologically-Based Pharmacokinetic Modeling. 2019 , 8, 931-939		3
151	Mortality After Paclitaxel-Coated Device Use in Dialysis Access: A Systematic Review and Meta-Analysis. 2019 , 26, 600-612		27
150	Molecular Mechanisms of Antitumor Activity of PAMAM Dendrimer Conjugates with Anticancer Drugs and a Monoclonal Antibody. 2019 , 11,		8
149	Hydrogel-Mediated DOX?HCl/PTX Delivery System for Breast Cancer Therapy. 2019 , 20,		8

148	Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography-tandem mass spectrometry. 2019 , 13, 1739-1749		1
147	In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations. 2019 , 565, 219-226		24
146	Paclitaxel interaction with cucurbit [7]uril and acyclic Cucurbit[4]uril nanocontainers: A computational approach. 2019 , 90, 210-218		2
145	Hyperthermia Nanofiber Platform Synergized by Sustained Release of Paclitaxel to Improve Antitumor Efficiency. 2019 , 8, e1900102		25
144	Antagonistic anticancer effect of paclitaxel and digoxin combination. 2019 , 120, 13107-13114		5
143	Phase II Study of a Bi-Weekly Chemotherapy Regimen of Combined Liposomal Paclitaxel and Nedaplatin for the Treatment of Advanced Squamous Cell Lung Cancer. 2019 , 12, 656-660		2
142	Exploitation of Fungal Endophytes as Bio-Factories for Production of Functional Metabolites through Metabolic Engineering; Emphasizing on Taxol Production. 2019 , 401-429		0
141	Prevention of paclitaxel-induced neuropathy by formulation approach. 2019 , 303, 109-116		17
140	Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. <i>Cancers</i> , 2019 , 11,	6.6	1
139	Plumbagin Increases Paclitaxel-Induced Cell Death and Overcomes Paclitaxel Resistance in Breast Cancer Cells through ERK-Mediated Apoptosis Induction. 2019 , 82, 878-885		16
138	Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer. 2019 , 9,		99
137	Downregulation of class II phosphoinositide 3-kinase PI3K-C2 β delays cell division and potentiates the effect of docetaxel on cancer cell growth. 2019 , 38, 472		8
136	Chloroplastic metabolic engineering coupled with isoprenoid pool enhancement for committed taxanes biosynthesis in <i>Nicotiana benthamiana</i> . 2019 , 10, 4850		35
135	AS1411 aptamer-modified theranostic liposomes co-encapsulating manganese oxide nano-contrast agent and paclitaxel for MRI and therapy of cancer.. 2019 , 9, 34837-34846		4
134	D-Optimal Optimization and Data-Analysis Comparison Between a DoE Software and Artificial Neural Networks of a Chitosan Coating Process onto PLGA Nanoparticles for Lung and Cervical Cancer Treatment. 2019 , 14, 206-220		4
133	Assessment of risk, extinction, and threats to Himalayan yew in Pakistan. 2020 , 27, 762-767		0
132	Conventional chemotherapy. 2020 , 127-153.e11		1
131	Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment. 2020 , 8, 564809		6

130	Polysaccharide from spore of <i>Ganoderma lucidum</i> ameliorates paclitaxel-induced intestinal barrier injury: Apoptosis inhibition by reversing microtubule polymerization. 2020 , 130, 110539	15
129	<i>Elephantopus mollis</i> Kunth extracts induce antiproliferation and apoptosis in human lung cancer and myeloid leukemia cells. 2020 , 263, 113222	4
128	EBV-miR-BART12 accelerates migration and invasion in EBV-associated cancer cells by targeting tubulin polymerization-promoting protein 1. 2020 , 34, 16205-16223	14
127	New solutions using natural products. 2020 , 263-351	
126	Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells. 2020 , 25,	16
125	Molecular Interpretation of Pharmaceuticals Adsorption on Carbon Nanomaterials: Theory Meets Experiments. 2020 , 8, 642	14
124	The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids. 2020 , 13, 6017-6025	5
123	Conjugation of Taxol with Porphyrin Increases the Anticancer Activity of Taxol and Ameliorates Its Cytotoxic Effects. 2020 , 25,	14
122	Hitherto Unknown Terpene Synthase Organization in Taxol-Producing Endophytic Bacteria Isolated from Marine Macroalgae. 2020 , 77, 918-923	5
121	Taxane anticancer formulations: challenges and achievements. 2020 , 347-358	
120	Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways. 2016 , 7, 42353-42373	13
119	Higher Plant Sources of Cancer Chemotherapeutic Agents and the Potential Role of Biotechnological Approaches for Their Supply. 2021 , 545-581	
118	Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis. 2021 , 12, 5164-5172	1
117	History and emerging trends in chemotherapy for gastric cancer. 2021 , 5, 446-456	4
116	Weed-Associated Fungal Endophytes as Biocontrol Agents of <i>f. sp. TR4</i> in Cavendish Banana. 2021 , 7,	2
115	Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy. 2021 , 9, 626910	4
114	Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects. 2021 , 12, S231-S239	4
113	Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. 2021 , 9,	5

112	Theoretical insights into the cineole-based deep eutectic solvents. 2021 , 154, 184504	3
111	Metabolic Engineering of Escherichia coli. 2021 , 339-402	
110	Salicylic Acid-Responsive Factor Positively Regulates Taxol Biosynthesis in in Direct and Indirect Ways. 2021 , 12, 697476	0
109	Dendrimeric Structures in the Synthesis of Fine Chemicals. 2021 , 14,	0
108	Chirality and Biological Activity. 2003 , 781-826	1
107	New chemotherapeutic agents for breast cancer. 1994 , 74, 1164-1176	11
106	DNA and RNA Binding Small Molecules. 164-205	2
105	Intraperitoneal taxol. 1996 , 81, 1-5	9
104	Taxoid compounds in breast cancer: current status and future prospects. 1995 , 78, 185-207	2
103	Experimental therapeutic approaches for recurrent head and neck cancer. 1995 , 74, 263-81	3
102	New antineoplastic agents in lung cancer 1988-1993. 1994 , 323-347	2
101	Natural Products, Complexity, and Evolution. 1996 , 265-293	7
100	Central Nervous System Complications of Cancer Therapy. 2003 , 215-231	6
99	Antimicrotubule Agents. 2008 , 177-205	1
98	Microtubule Stabilizing Agents in Clinical Oncology. 2008 , 395-419	2
97	Secondary Metabolite Production from Plant Cell Cultures: the Success Stories of Rosmarinic Acid and Taxol. 2008 , 85-100	4
96	Increasing Secondary Metabolite Production by In Vivo Extraction and Elicitation. 1992 , 254-257	1
95	Taxol. 1995 , 9, 1-21	1

94	Chemical Studies of the Taxane Diterpenes. 1993 , 12, 179-231	6
93	Epithelial Ovarian Cancer. 2007 , 313-367	7
92	Site-specific enzymatic hydrolysis of taxanes at C-10 and C-13.. 1994 , 269, 22145-22149	26
91	Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain.. 1994 , 269, 31785-31792	61
90	Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau.. 1993 , 268, 6847-6850	109
89	Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. 1994 , 5, 495-505	253
88	Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). 1998 , 21, 553-6	21
87	Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. 1999 , 22, 517-22	44
86	Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. 2000 , 23, 349-52	13
85	Paclitaxel in Advanced Urothelial Carcinoma. 1996 , 1606-1608	2
84	Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in brain tumor therapy. 1997 , 40, 1260-6; discussion 1266-8	30
83	Chemotherapy-induced peripheral neuropathy in a dish: dorsal root ganglion cells treated in vitro with paclitaxel show biochemical and physiological responses parallel to that seen in vivo. 2021 , 162, 84-96	5
82	Cancer chemotherapy: identifying novel anticancer drugs. 1994 , 308, 1288-90	9
81	Protective effect of a microtubule stabilizer taxol on caerulein-induced acute pancreatitis in rat. 1992 , 89, 234-43	29
80	Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. 1995 , 95, 1869-76	187
79	Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis. 2012 , 7, e51526	16
78	Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. 2013 , 8, e58037	18
77	Statistical Evaluation of HTS Assays for Enzymatic Hydrolysis of β Keto Esters. 2016 , 11, e0146104	7

76	Effect of taxol on chromosome aberrations induced by gamma radiation or by doxorubicin in Chinese hamster ovary cells. 1997 , 20, 389-395	1
75	Paclitaxel in Breast Cancer. 1998 , 3, 373-389	96
74	Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer. 1999 , 4, 408-416	49
73	The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer. 2014 , 5, 3246-60	13
72	, a microtubule-associated protein, promotes tumor growth and progression of human gastric cancer. 2017 , 8, 74479-74493	14
71	Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling. 2015 , 6, 21906-17	21
70	Clinical characteristics of colitis induced by taxane-based chemotherapy. 2020 , 33, 59-67	6
69	Rapid and Efficient in vitro Germination of Embryos from <i>Taxus media</i> Rehder. 2005 , 5, 139-141	3
68	Rapid and sensitive liquid chromatographic method for determination of Paclitaxel from parenteral formulation and nanoparticles. 2010 , 72, 465-70	7
67	A multi-center, phase ii clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. 2005 , 37, 349-53	8
66	Intraperitoneal Chemotherapy as a Multimodal Treatment for Gastric Cancer Patients with Peritoneal Metastasis. 2013 , 04, 6-15	7
65	Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes. 2015 , 7, 285-91	20
64	A drug-coated balloon treatment for urethral stricture disease: Interim results from the ROBUST I study. 2020 , 14, 187-191	9
63	Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles. 2016 , 71, 435-9	21
62	Combination between Taxol-Encapsulated Liposomes and <i>Eruca sativa</i> Seed Extract Suppresses Mammary Tumors in Female Rats Induced by 7,12 Dimethylbenz(a)anthracene. 2016 , 17, 117-23	7
61	Decreasing Particle Size of Paclitaxel Using Polymer in Fractional Precipitation Process. 2016 , 54, 278-283	2
60	Medicinal potentialities and pathogenic profile of <i>Lasiodiplotia</i> genus. 2021 , 37, 190	
59	Hyaluronic acid coated Pluronic F127/Pluronic P123 mixed micelle for targeted delivery of Paclitaxel and Curcumin. 2021 , 192, 950-957	3

- 58 Radiopharmaceuticals for Tumor-Targeted Imaging: Overview. **2001**, 62-82
- 57 Relief of paclitaxel-induced arthralgia and myalgia with oral prednisone in patients with ovarian cancer. **2002**, 14, 29-31
- 56 Terrestrial plant species with anticancer activity. **2004**, 35-194
- 55 Systemische Therapie des metastasierten Mammakarzinoms. **2006**, 335-353
- 54 The efficacy and safety of Padexol (paclitaxel) and cisplatin for treating advanced non-small cell lung cancer. **2006**, 38, 66-71 2
- 53 Modes of Action at Target Sites. **2006**, 415-440
- 52 Systemische Therapie des metastasierten Mammakarzinoms. **2010**, 228-246
- 51 DRUGS USED IN CANCER CHEMOTHERAPY. **2010**, 1-229
- 50 Natural Products. 1 0
- 49 Combinatorial Chemistry in the Drug Discovery Process. 1
- 48 Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer. **2011**, 281-291 1
- 47 A case of gastric cancer with para-aortic lymphnode metastasis responding to preoperative chemotherapy completely on pathology and surviving 5 years without recurrence. **2013**, 74, 75-80 1
- 46 U. **2013**, 883-894
- 45 Chemotherapeutic Engineering. **2014**, 21-80
- 44 Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination. **1991**, 441-452
- 43 Current Strategies in Anticancer Drug Discovery Within the EORTC. **1992**, 93-103
- 42 Systemic Treatment of Metastatic Malignant Melanoma. **1992**, 135-156 1
- 41 New Chemotherapeutic Agents: A Selection of Some of the Most Promising New Drugs. **1993**, 335-346

- 40 Preclinical Pharmacology and Phase I Clinical Trials of TaxotereR (RP 56976, NSC 628503). **1994**, 283-297
- 39 Multiple Cell Cycle Checkpoint Override and its Potential for Binary Tumor Therapy. **1994**, 389-396
- 38 Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer. **1995**, 215-223
- 37 Clinical Neurotoxic Concerns on Antineoplastic Agents. **1995**, 657-670
- 36 The Taxoids. **1997**, 175-193
- 35 Apoptosis Induced by Microtubular Poisons in Thymocytes. **1997**, 87-93
- 34 Prodrugs. **1999**, 177-192
- 33 Chemotherapy and Chemoradiotherapy. **2015**, 197-225 1
- 32 Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer. **2016**, 337-348
- 31 Current and Emerging Role of Chemotherapy in Oral Cancer. **2017**, 127-146 1
- 30 Bibliography. **2017**, 217-244
- 29 Chemotherapy and Chemoradiotherapy. **2020**, 253-282
- 28 Taxol dose intensification and its clinical implications. **1993**, 85, 427-31 15
- 27 Taxol: an important new drug in the management of epithelial ovarian cancer. **1991**, 64, 583-90 30
- 26 Transport Behavior of Commercial Anticancer Drug Protein-Bound Paclitaxel (Paclicad) in a Micron-Sized Channel.. **2022**,
- 25 Molecular mechanisms associated with chemoresistance in esophageal cancer.. **2022**, 79, 116 1
- 24 Paclitaxel Drug Delivery Systems: Focus on Nanocrystals' Surface Modifications.. **2022**, 14, 4
- 23 An update on EUS-guided ablative techniques for pancreatic cystic lesions.. **2022**, 1

22	Paclitaxel resistance is mediated by NF- κ B on mesenchymal primary breast cancer cells.. <i>Oncology Letters</i> , 2022 , 23, 50	2.6	0
21	Can We Reboot the Role of Intraperitoneal Chemotherapy in the Treatment for Gastric Cancer with Peritoneal Carcinomatosis?: A Retrospective Cohort Study Regarding Minimally Invasive Surgery Conjoined with Intraperitoneal plus Systemic Chemotherapy.. <i>Cancers</i> , 2022 , 14,	6.6	
20	Class III β Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. <i>Pancreas</i> , Publish Ahead of Print,	2.6	0
19	Effect of Paclitaxel Stereochemistry on X-ray-Triggered Release of Paclitaxel from CaWO ₄ /Paclitaxel-Coloaded PEG-PLA Nanoparticles. <i>Molecular Pharmaceutics</i> ,	5.6	0
18	Triple negative breast cancer: approved treatment options and their mechanisms of action.		1
17	Hydroxypropyl Beta Cyclodextrin as a Potential Surface Modifier for Paclitaxel Nanocrystals. 2022 , 23,		
16	Rottlerin promotes anti-metastatic events by ameliorating pharmacological parameters of paclitaxel: An in-vivo investigation in the orthotopic mouse model of breast cancer. 2022 , 366, 110109		0
15	An overview of paclitaxel and molecular imprinted polymers capped with Quantum Dots as an alternative approach for paclitaxel extraction and detection. 2022 , 15,		0
14	A new core-shell-type nanoparticle loaded with paclitaxel/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma. 12,		0
13	ZASTOSOWANIA KLINICZNE PAKLITAKSELU W TERAPII NOWOTWORŃ. 2021 , 19, 9-17		0
12	Adsorptive Removal of Paclitaxel from Pharmaceutical Effluent Via Fabricated Magnetic MWCNT and Graphene Oxide Nanocomposites.		0
11	An Overview on Taxol Production Technology and Its Applications as Anticancer Agent.		1
10	Recent Developments and Anticancer Therapeutics of Paclitaxel: An update. 2022 , 29,		0
9	Sustained release system of paclitaxel based on composite nanofibers for inhibiting renal clear cell carcinoma.		0
8	<i>Taxus baccata</i> subsp. <i>wallichiana</i> (Zucc.) Pilg.. 2023 , 419-434		0
7	Efforts in Bioprospecting Research: A Survey of Novel Anticancer Phytochemicals Reported in the Last Decade. 2022 , 27, 8307		0
6	Palmitoylethanolamide Mitigates Paclitaxel Toxicity in Primary Dorsal Root Ganglion Neurons. 2022 , 12, 1873		0
5	Perspective Chapter: Appraisal of Paclitaxel (Taxol) Pros and Cons in the Management of Cancer - Prospects in Drug Repurposing.		0

- 4 Paclitaxel exerts antiplatelet and antithrombotic activities: Additional benefit from use of paclitaxel-coated balloons and -eluting stents in coronary revascularization and prevention of in-stent restenosis. **2023**, 225, 63-72 ○
- 3 Tacrolimus and paclitaxel co-loaded O/O ointment without surfactant: Synergistic combinations for the treatment of psoriasis. **2023**, 185, 28-43 ○
- 2 Lactobacillus rhamnosus GG alleviates colitis caused by chemotherapy via biofilm formation. ○
- 1 Hyperbaric Oxygen Therapy Alleviates Paclitaxel-Induced Peripheral Neuropathy Involving Suppressing TLR4-MyD88-NF-B Signaling Pathway. **2023**, 24, 5379 ○